Sutro Biopharma Debt to Equity

The latest debt-to-equity ratio for STRO is -0.34. That is below the Healthcare sector average of 0.34. Investors often review this figure alongside Sutro Biopharma's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, STRO currently prints -0.34 for debt-to-equity ratio, while the sector average sits near 0.34. That is roughly 200.8% below the sector mean. Large gaps often invite a closer look at Sutro Biopharma's growth, margins, and balance sheet.

A debt-to-equity ratio of -0.34 for Sutro Biopharma is not 'good' or 'bad' on its own. Compare it with the peer average (0.34) and with STRO's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting STRO's debt-to-equity ratio (-0.34), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Sutro Biopharma's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.